As Promised, CytRx Spins Out RNAi Drug Business Into New Pure-Play Subsidiary

CytRx said as early as November 2005 that it planned to spin out the business into a new company, but lacked the cash to do so until a nonprofit paid it around $24 million in exchange for royalties for its investigational amyotrophic lateral sclerosis drug arimoclomol.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.